Melphalan hydrochloride for the treatment of multiple myeloma. (24th July 2017)

• Record Type: Journal Article
• Authors: Esma, Fabrizio; Salvini, Marco; Troia, Rossella; Boccadoro, Mario; Larocca, Alessandra; Pautasso, Chiara
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 11(2017)
• Page Start: 1127
• Page End: 1136
• Publication Date: 2017-07-24
• Subjects: Melphalan -- multiple myeloma -- pharmacodynamics -- pharmacokinetics -- chemistry -- combination; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2017.1349102
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell proliferation and overproduction of monoclonal paraprotein, hypercalcemia, renal failure, anemia, osteolytic bone lesions, and infections. Melphalan, a nitrogen mustard, is an alkylating agent synthesized in 1953, and it has been used in multiple myeloma therapy for fifty years. Although novel agents have been introduced in the past few decades improving prognosis of the disease, melphalan still maintains a crucial role in the treatment of MM acting both as cytotoxic agent through damage to DNA, and as immunostimulatory drug by inhibiting Interleukin-6, as well as interaction with dendritic cells, and immunogenic effects in tumor microenvironment. Areas covered : This review focuses on available data about melphalan pharmacology and its role in clinical practice. Expert opinion : Melphalan remains crucial in therapy of multiple myeloma because of its good manageability, safety profile, efficacy, and economic sustainability. These characteristics make it pivotal also for new regimens in combination with novel agents.